Navigation Links
Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031
Date:1/6/2011

Cambridge, Mass. Jan. 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy (DMD), a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by blocking proteins that inhibit muscle growth and strength.

"We are honored to be recognized and supported by the Muscular Dystrophy Association as we work collectively to develop promising therapies for the treatment of patients with Duchenne Muscular Dystrophy," said John Knopf, PhD, CEO of Acceleron. "This award along with our collaboration with Shire brings together the resources of several committed groups to evaluate the therapeutic potential of ACE-031 in DMD."

"Having invested more than $164 million on DMD-related research, MDA is eager to help Acceleron advance the clinical trial work needed to determine optimal doses of ACE-031 in terms of safety and pharmacodynamic activity," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.

The MDA grant, awarded through the Association's Venture Philanthropy Program (MVP), will support ongoing clinical studies of ACE-031 in boys with DMD. The new investment will enable Acceleron to gather safe dosing and pharmcodynamic activity information vital to future studies of ACE-031. For more information on these ongoing studies, visit clinicaltrials.gov and query study identifiers NCT01099761 and NCT01239758.

"MDA is pleased to support Acceleron's efforts in the fight against Duchenne Muscular Dystrophy," said Valerie Cwik, M.D., MDA Executive Vice President Research and Medical Director. "Our strategic investment should help Acceleron expedite the next phase of ACE-031 human clinical trials."


'/>"/>

Contact: Jim Brown
jbrown@mdausa.org
520-529-5317
Muscular Dystrophy Association
Source:Eurekalert

Related biology news :

1. Stevens awarded $1M for advanced biofuels research
2. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
3. BIO-keys(R) Law Enforcement Group Awarded $700,000 in New Contracts
4. Broad Institute awarded major grant to bolster epigenomics research
5. LSUHSC awarded patent for compound inhibiting cancer and other diseases
6. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
7. Field-hospital-on-a-chip project awarded to nanoengineer from UC San Diego
8. SAIC Awarded $37 Million Contract to Support U.S. Army Program Executive Office - Enterprise Information Systems
9. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
10. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
11. BIO-key(R) Awarded PocketCop(R) Contracts From Major Law Enforcement Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
Breaking Biology Technology: